Endospan Revenue and Competitors

The NEXUS Aortic Arch Stent Graft System by Endospan is the first and only CE-approved off-the-shelf branched endovascular aortic arch system. Indicated for wide range of aortic pathologies, including arch aneurysms, thoracic dissections, and PAU, NEXUS is designed to overcome the specific challenges of the aortic arch anatomy. The NEXUS “Dock and Lock” modular system provides stable and secured anatomical anchoring and atraumatic sealing in a wide range of anatomies. Privately held Endospan, headquartered in Herzlia (Tel Aviv), Israel, is a pioneer in the endovascular repair of aortic arch disease including aneurysms and dissections. Endospan's NEXUSTM Aortic Arch Stent Graft System is the first endovascular off-the-shelf system with CE Mark to treat a greatly underserved group of patients diagnosed with a dilative lesion in, or near the aortic arch. While minimally invasive endovascular repair has been the standard of care for Abdominal Aortic Aneurysm (AAA), Aortic Arch Disease patients with aneurysms or dissections have not been as fortunate and have had little choice but to undergo open-chest surgery with its invasiveness and risks, lengthy hospitalization periods, and prolonged recuperation. For additional information about Endospan, visit their website at www.endospan.com.